| Description | This product is a neutralizing antibody that binds to Severe Acute Respiratory Syndrome Coronavirus 2. C022 IgGs recognize and neutralize diverse sarbecoviruses, including SARS-CoV-2 variants. C022 recognize a highly conserved epitope and are therefore likely to be class 4 anti-RBD antibodies. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | RBD receptor binding domain |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA |
| Application Notes | Purified RBD at 10 μg/ml in 0.1 M NaHCO3 was coated onto Nunc MaxiSorp 384-well plates and stored overnight at 4_x005f_x0004_°C. The following day, plates were blocked with 3% BSA in TBS-T Buffer for 1hr at room temperature. Blocking solution was removed from the plates, purified IgGs at 50 μg/mL were serially diluted by 4-fold with TBS-T/3% BSA and added to plates for 3 hr at room temperature. Plates were washed with TBS-T and then incubated with 1:15,000 dilution of secondary HRP-conjugated goat anti-human IgG for 45 minutes at room temperature. Plates were washed again with TBS-T and developed using SuperSignal ELISA Femto Maximum Sensitivity Substrate and read at 425 nm. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
